Q2 2026 saw 6% revenue growth and 8% adjusted EBITDA growth year-over-year, driven by strong ADHD and pain portfolio performance and the successful integration of AZSTARYS. Updated 2026 guidance projects $825–855M in revenue and $445–470M in adjusted EBITDA.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.